Eisai Co. Ltd (EII F) stock market data APIs
€23.442
0.07(0.3%)
as of January 29, 2026
Try our APIs with
free plan!
Eisai Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
23.442
Open
23.5139
High
23.5522
Low
23.384
52 wk Range
-51.13-30.9057
Market Cap
6 674 M
P/E Ratio
24.2708
Shares Outstanding
282 M
Revenue
804 390 M
EPS
84.31
Dividends (Yield)
0.0404
Beta
-0.26
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd data using free add-ons & libraries
Get Eisai Co. Ltd Fundamental Data
Eisai Co. Ltd Fundamental data includes:
- Net Revenue: 804 390 M
- EBITDA: 93 028 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-06
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd News
New
Eisai: Canada's Drug Agency Recommendation Denies Canadians Safer Insomnia Treatments
MISSISSAUGA, ON, Jan. 29, 2026 /CNW/ - Eisai Limited, a leading research and development-based pharmaceutical company specializing in neurology and oncology, is deeply disappointed by Canada's Drug Ag...
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation t...
Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative
Eisai and Biogen recently announced that the U.S. FDA has accepted for Priority Review a supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous weekly autoinjector starting dose ...
Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
STOCKHOLM, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous aut...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
